Health Canada Approves Apotex's CLOBIVIS for Post-Cataract Surgery Inflammation Treatment
Key Insights
Health Canada has approved CLOBIVIS (search) (clobetasol propionate ophthalmic suspension, 0.05%) for treating postoperative inflammation (search) and pain following cataract surgery (search).
The drug is formulated using nanoparticle technology to deliver a uniform ophthalmic suspension and was licensed from Formosa (search) by Apotex (search).
This approval represents a significant expansion of Apotex (search)'s ophthalmology portfolio and reinforces the company's commitment to improving access to innovative treatments for Canadian patients.
Apotex (search) Inc., Canada's largest pharmaceutical company, announced that Health Canada has approved CLOBIVIS (search) (clobetasol propionate ophthalmic suspension, 0.05%) for the treatment of postoperative inflammation (search) and pain following cataract surgery (search). The approval marks a significant milestone in expanding ophthalmic treatment options for Canadian patients.
Advanced Formulation Technology
CLOBIVIS (search) is formulated using nanoparticle technology to deliver a uniform ophthalmic suspension. The drug was licensed from Formosa (search) and represents an innovative approach to managing post-surgical complications in cataract patients. The 0.05% concentration provides targeted anti-inflammatory treatment specifically designed for ophthalmic use.
Strategic Portfolio Expansion
The approval enhances Apotex (search)'s growing ophthalmology portfolio and demonstrates the company's strategic focus on expanding therapeutic options through partnerships. "As a Force for Health, Apotex seeks to ensure patients have access to innovative treatments," said Martin Arès, President, Apotex Canada and Rest of World. "The approval of CLOBIVIS (search) is another milestone in broadening the availability of ophthalmology medicines through strategic partnerships that support ophthalmic care for Canadians, and it reflects our Journey of Health Strategy to expand access to new therapies."
Clinical Application and Safety
Healthcare professionals are advised to refer to the complete Product Monograph for detailed information on warnings, precautions, adverse reactions, and patient monitoring requirements. The approval provides ophthalmologists and eye care specialists with an additional treatment option for managing the inflammatory response that commonly occurs following cataract surgery (search) procedures.
Company Background
Apotex (search) operates as a global health company headquartered in Toronto, with regional offices in the United States, Mexico, and India. The company maintains a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, along with consumer health products, serving millions of patients worldwide through improved access to affordable medicines.